MA27568A1 - Derives de pyrrolopyrimidine - Google Patents

Derives de pyrrolopyrimidine

Info

Publication number
MA27568A1
MA27568A1 MA28346A MA28346A MA27568A1 MA 27568 A1 MA27568 A1 MA 27568A1 MA 28346 A MA28346 A MA 28346A MA 28346 A MA28346 A MA 28346A MA 27568 A1 MA27568 A1 MA 27568A1
Authority
MA
Morocco
Prior art keywords
formula
compounds
pyrrolopyrimidine derivatives
relates
pyrrolopyrimidine
Prior art date
Application number
MA28346A
Other languages
English (en)
Inventor
Joel Thomas Arcari
Jinshan Chen
Susan Lagreca
Matthew Arnold Marx
Matthew David Wessel
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32682064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27568(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27568A1 publication Critical patent/MA27568A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Dérivés de pyrrolopyrimidine L'invention concerne des composés de formule 1 ou un de leurs sels, précurseurs médicamenteux ou hydrates pharmaceutiquement acceptables, formule dans laquelle Q, A, L, R1, R2 et R3 répondent aux définitions figurant dans le présent mémoire. L'invention concerne également des compositions pharmaceutiques contenant les composés de formule 1 et des méthodes pour le traitement de troubles hyperprolifératifs chez un mammifère par administration des composés de formule 1.
MA28346A 2002-12-19 2005-06-17 Derives de pyrrolopyrimidine MA27568A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43456802P 2002-12-19 2002-12-19

Publications (1)

Publication Number Publication Date
MA27568A1 true MA27568A1 (fr) 2005-10-03

Family

ID=32682064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28346A MA27568A1 (fr) 2002-12-19 2005-06-17 Derives de pyrrolopyrimidine

Country Status (34)

Country Link
US (1) US7271262B2 (fr)
EP (1) EP1578751B1 (fr)
JP (1) JP4057013B2 (fr)
KR (2) KR20050084402A (fr)
CN (1) CN1726218A (fr)
AP (1) AP2005003342A0 (fr)
AR (1) AR042509A1 (fr)
AT (1) ATE512965T1 (fr)
AU (1) AU2003286317A1 (fr)
BR (1) BR0317524A (fr)
CA (1) CA2510853C (fr)
EA (1) EA200500814A1 (fr)
EC (1) ECSP055867A (fr)
ES (1) ES2364649T3 (fr)
GT (1) GT200300289A (fr)
HN (1) HN2003000416A (fr)
HR (1) HRP20050560A2 (fr)
IS (1) IS7872A (fr)
MA (1) MA27568A1 (fr)
MX (1) MXPA05006793A (fr)
NL (1) NL1025068C2 (fr)
NO (1) NO20052802L (fr)
NZ (1) NZ540456A (fr)
OA (1) OA12976A (fr)
PA (1) PA8591701A1 (fr)
PE (1) PE20040914A1 (fr)
PL (1) PL377774A1 (fr)
RS (1) RS20050469A (fr)
TN (1) TNSN05165A1 (fr)
TW (1) TW200423939A (fr)
UA (1) UA80171C2 (fr)
UY (1) UY28132A1 (fr)
WO (1) WO2004056830A1 (fr)
ZA (1) ZA200504440B (fr)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100872204B1 (ko) * 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
CA2546192C (fr) 2003-11-17 2010-04-06 Pfizer Products Inc. Composes de pyrrolopyrimidine utiles dans le traitement du cancer
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MXPA06013805A (es) * 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
WO2006076592A1 (fr) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. Urees a substitution 1,3-diaryle, modulateurs de l'activite de kinases
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
WO2007024294A2 (fr) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certains urees substitues, modulateurs de l'activite des kinases
US7795248B2 (en) 2005-05-18 2010-09-14 Abbott Laboratories, Inc. Substituted 7,8-dihydro-1H-pyrimido[4,5-B][1,4]diazepin-4-amines are novel kinase inhibitors
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
EP1928843A1 (fr) * 2005-08-22 2008-06-11 Amgen, Inc Composes d'uree de bis-aryle pour le traitement de maladies mediees par une proteine kinase
BRPI0617863A2 (pt) * 2005-10-28 2011-08-09 Irm Llc compostos e composições como inibidores da proteìna quinase
EP2385053B1 (fr) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermédiaires pour la préparation de composés bicycliques condensés comme inhibiteurs mTOR
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
WO2007066189A2 (fr) * 2005-12-09 2007-06-14 Pfizer Products Inc. Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
JP2009520028A (ja) * 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
TW200801008A (en) * 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2008076143A1 (fr) * 2006-12-18 2008-06-26 Osi Pharmaceuticals, Inc. Combinaison d'un inhibiteur de l'igfr et d'un agent anticancéreux
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
US8993580B2 (en) * 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
EP2283020B8 (fr) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Imidazopyrazines et imidazotriazines substituées
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
WO2009143018A2 (fr) 2008-05-19 2009-11-26 Plexxikon, Inc. Composés et procédés de modulation des kinases, et indications associées
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
US8119637B2 (en) * 2008-06-10 2012-02-21 Plexxikon Inc. Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
EP2307456B1 (fr) 2008-06-27 2014-10-15 Amgen Inc. Inhibition de l ang-2 pour traiter la sclérose en plaques
JP5788316B2 (ja) 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
WO2010045542A2 (fr) * 2008-10-16 2010-04-22 The Regents Of The University Of California Inhibiteurs d'hétéroarylkinase à noyau fusionné
US8476431B2 (en) * 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
EP2408479A1 (fr) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
WO2010123792A1 (fr) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Préparation de c-pyrazine-méthylamines
EP2427192A1 (fr) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8673928B2 (en) 2009-11-18 2014-03-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
JP2013516420A (ja) 2009-12-30 2013-05-13 アークル インコーポレイテッド 置換されたピロロ−アミノピリミジン化合物
WO2011153553A2 (fr) * 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
CA2816753A1 (fr) 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline et composes bicycliques associes pour l'inhibition de l'activite rorg et le traitement de maladies
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2012129145A1 (fr) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Polythérapie du cancer du poumon non à petites cellules (nsclc)
ES2581848T3 (es) 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
US9138436B2 (en) * 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CA2846574C (fr) 2011-08-26 2020-07-07 Neupharma, Inc. Derives de sulfonamide de quinoxaline destines a une utilisation comme inhibiteurs de kinase
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CN108794411B (zh) * 2011-09-14 2022-06-07 润新生物公司 某些化学实体、组合物及方法
CA2862163A1 (fr) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Phenylimidazopyrazoles substitues et leur utilisation
EP2806874B1 (fr) 2012-01-25 2017-11-15 Neupharma, Inc. Dérivés de quinoxaline-oxy-phenyl comme inhibiteurs de kinases
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
AU2013259737A1 (en) 2012-05-08 2014-10-02 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP2897618B1 (fr) 2012-09-24 2021-11-17 Neupharma, Inc. Entités chimiques particulières, compositions et procédés
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
EP2903989A1 (fr) 2012-10-04 2015-08-12 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[2,3-d]pyrimidine
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
EP2912036A1 (fr) 2012-10-04 2015-09-02 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014153509A1 (fr) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
WO2015095795A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Tétrahydronaphtyridine, benzoxazine, aza-benzoxazine et composés bicycliques apparentés pour l'inhibition de l'activité de rorgamma et le traitement de maladie
US20170305857A1 (en) 2013-12-20 2017-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
WO2015170218A1 (fr) 2014-05-07 2015-11-12 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2792036T3 (es) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de cinasa
EP3256450B1 (fr) 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Composés pyrazole substitués utilisés en tant qu'inhibiteurs de ror-gamma-t et utilisations desdits composés
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3269367B1 (fr) * 2015-03-11 2020-10-07 Riken Agent thérapeutique contre la leucémie réfractaire
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
WO2017075178A1 (fr) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Composés pyrazoles bicycliques substitués en tant qu'inhibiteurs de rorgammat et leurs utilisations
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
JP7011596B2 (ja) * 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017133669A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés 5,7-diazaindole et 5,7-diazaindazole et leur utilisation pour traiter, atténuer ou prévenir la grippe
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN110461849B (zh) * 2017-06-19 2020-09-01 上海和誉生物医药科技有限公司 一种csf1r抑制剂及其制备方法和应用
US11518761B2 (en) 2017-08-17 2022-12-06 Vyera Pharmaceuticals, LLC CDPK1 inhibitors, compositions, and methods related thereto
JP7033143B2 (ja) 2017-08-21 2022-03-09 大鵬薬品工業株式会社 Ｄｃｔｎ１タンパク質とｒｅｔタンパク質との融合タンパク質
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
CN112574200B (zh) 2021-02-26 2021-06-11 安润医药科技（苏州）有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2022261159A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981458A (en) * 1961-12-04 1965-01-27 Wellcome Found Pyrrolo[2,3-d]pyrimidines
US4218374A (en) * 1972-10-20 1980-08-19 Fujisawa Pharmaceutical Company, Limited Penam derivatives
DE3145287A1 (de) * 1981-11-14 1983-05-19 Troponwerke GmbH & Co KG, 5000 Köln Pyrrolo (2.3-d)pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU1794697A (en) * 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
ES2203793T3 (es) * 1996-03-15 2004-04-16 Novartis Ag N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.
DK0970084T3 (da) * 1997-03-19 2003-09-29 Abbott Gmbh & Co Kg Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase
CA2344249A1 (fr) 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines utilisees comme inhibiteurs de proteines kinases
CA2344262A1 (fr) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft 4-aminopyrrolopyrimidines utilisees comme inhibiteurs de kinases
WO2001072751A1 (fr) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
WO2002000651A2 (fr) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa
MXPA04007832A (es) * 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.

Also Published As

Publication number Publication date
NO20052802D0 (no) 2005-06-09
ES2364649T3 (es) 2011-09-08
NZ540456A (en) 2007-11-30
PL377774A1 (pl) 2006-02-20
AU2003286317A1 (en) 2004-07-14
EA200500814A1 (ru) 2006-02-24
PA8591701A1 (es) 2005-05-24
TNSN05165A1 (fr) 2007-05-14
JP2006512356A (ja) 2006-04-13
MXPA05006793A (es) 2005-09-08
CN1726218A (zh) 2006-01-25
AR042509A1 (es) 2005-06-22
OA12976A (en) 2006-10-13
HRP20050560A2 (en) 2006-02-28
BR0317524A (pt) 2005-11-16
AP2005003342A0 (en) 2005-06-30
ATE512965T1 (de) 2011-07-15
RS20050469A (sr) 2007-11-15
NO20052802L (no) 2005-07-19
IS7872A (is) 2005-05-30
CA2510853C (fr) 2009-04-28
HN2003000416A (es) 2006-07-25
CA2510853A1 (fr) 2004-07-08
US20050037999A1 (en) 2005-02-17
NL1025068A1 (nl) 2004-06-22
WO2004056830A1 (fr) 2004-07-08
TW200423939A (en) 2004-11-16
UY28132A1 (es) 2004-07-30
KR20050084402A (ko) 2005-08-26
EP1578751B1 (fr) 2011-06-15
UA80171C2 (en) 2007-08-27
KR20070087020A (ko) 2007-08-27
ZA200504440B (en) 2006-07-26
JP4057013B2 (ja) 2008-03-05
US7271262B2 (en) 2007-09-18
NL1025068C2 (nl) 2004-11-16
EP1578751A1 (fr) 2005-09-28
PE20040914A1 (es) 2005-01-08
ECSP055867A (es) 2005-09-20
GT200300289A (es) 2004-09-21

Similar Documents

Publication Publication Date Title
MA27568A1 (fr) Derives de pyrrolopyrimidine
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31373B1 (fr) Composes amino-heterocycliques
MA28747B1 (fr) Dérivés de pyridine
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA29926B1 (fr) Derives de pyrazine
TNSN05250A1 (fr) Pyrimidinones substituees
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
NL300207I2 (nl) Esters van 5-aminolevulinezuur als fotosensibiliserende middelen in de fotochemotherapie.
MA27775A1 (fr) Composes organiques
MA31754B1 (fr) Cis-imidazolines chirales
MA28094A1 (fr) Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MY130668A (en) Isothiazole derivatives useful as anticancer agents
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TNSN06439A1 (fr) Derives de 2-carbamide -4-phenylthiazole, leur preparation et leur application en therapeutique
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97044A1 (fr) Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant.
TW200738698A (en) Organic compounds
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
MA27716A1 (fr) 4-aminopyrimidine-5-one